







Classical psychedelics are psychoactive substances, which, besides their psychopharmacological activity, have also been shown to exert significant modulatory effects on immune responses by altering signaling pathways involved in inflammation, cellular proliferation and cell survival via activating NF-κB and MAPKs. Recently, several neurotransmitter receptors involved in the pharmacology of psychedelics, such as serotonin and sigma-1 receptors, have also been shown to play crucial roles in numerous immunological processes. This emerging field also offers promising treatment modalities in the therapy of various diseases including autoimmune and chronic inflammatory conditions, infections, and cancer. However, the scarcity of available review literature renders the topic unclear and obscure, mostly posing psychedelics as illicit drugs of abuse and not as physiologically relevant molecules or as possible agents of future pharmacotherapies. In this paper, the immunomodulatory potential of classical serotonergic psychedelics, including N,N-dimethyltryptamine (DMT), 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT), lysergic acid diethylamide (LSD), 2,5-dimethoxy-4-iodoamphetamine (DOI) and 3,4-methylenedioxy-methamphetamine (MDMA) will be discussed from a perspective of molecular immunology and pharmacology. Special attention will be given to the functional interaction of serotonin and sigma-1 receptors and their cross-talk with Toll-like and RIG-I-like pattern recognition receptor-mediated signaling. Furthermore, novel approaches will be suggested feasible for the treatment of diseases with chronic inflammatory etiology and pathology, such as atherosclerosis, rheumatoid arthritis, multiple sclerosis, schizophrenia, depression and Alzheimer's disease.
Psychedelics reopen the social reward learning critical period
Psychedelics are a broad class of drugs defined by their ability to induce an altered state of consciousness1,2. These drugs have been used for millennia in both spiritual and medicinal contexts, and a number of recent clinical successes have spurred a renewed interest in developing psychedelic therapies3–9. Nevertheless, a unifying mechanism that can account for these shared phenomenological and therapeutic properties remains unknown. Here we demonstrate in mice that the ability to reopen the social reward learning critical period is a shared property across psychedelic drugs. Notably, the time course of critical period reopening is proportional to the duration of acute subjective effects reported in humans. Furthermore, the ability to reinstate social reward learning in adulthood is paralleled by metaplastic restoration of oxytocin-mediated long-term depression in the nucleus accumbens. Finally, identification of differentially expressed genes in the ‘open state’ versus the ‘closed state’ provides evidence that reorganization of the extracellular matrix is a common downstream mechanism underlying psychedelic drug-mediated critical period reopening. Together these results have important implications for the implementation of psychedelics in clinical practice, as well as the design of novel compounds for the treatment of neuropsychiatric disease.

A Dose of a Hallucinogen From a ‘Magic Mushroom,’ and Then Lasting Peace (Published 2016)
Two studies used psilocybin to see if the drug could reduce depression and anxiety in cancer patients. The results were striking.

A single high dose of psilocybin alters brain function up to one month later
New research provides evidence that the active ingredient in so-called magic mushrooms can affect brain processes related to emotional functioning long

New psychedelic research sheds light on why psilocybin-containing mushrooms have been consumed for centuries
A new study from the Center for Psychedelic and Consciousness Research at Johns Hopkins University School of Medicine provides insight into the

Researchers are giving religious leaders psychedelic drugs in the interest of science
Despite the fact that psychedelic drugs have been used for millennia as medicine in ritualistic ceremonies, there remain many questions in the scientific community about the relationship between their spiritual qualities and healing potential. Researchers at Johns Hopkins and New York Universities are giving psilocybin, the active ingredient in magic mushrooms, to ordained ministers in the hopes that they can help provide some answers.

From treating PTSD to quitting tobacco: researchers say public investment into psychedelic drugs essential | CBC News
Magic mushrooms to treat depression, ecstasy to cure PTSD and LSD to combat alcoholism; just some of the drug-affliction pairings that have been tested in recent years.

Magic Mushroom Drug Lifts Depression in Human Trial
Psilocybin shows higher remission rate than SSRI drugs in a U.K. study

Methylenedioxymethamphetamine (‘Ecstasy’)-induced immunosuppression: a cause for concern?
Methylenedioxymethamphetamine (MDMA; ‘Ecstasy’) is a ring-substituted amphetamine and a popular drug of abuse. In addition to ability to induce euphoria, MDMA abuse is associated with a range of acute and long-term hazardous effects. This paper is focused on once such adverse effect: its ability to negatively impact on functioning of the immune system. Research demonstrates that MDMA has immunosuppressive properties, with both innate and adaptive arms of the immune system being affected. The ability of MDMA to suppress innate immunity is indicated by impaired neutrophil phagocytosis and reduced production of dendritic cell/macrophage-derived pro-inflammatory cytokines including tumour necrosis factor-alpha, interleukin (IL)-1β, IL-12 and IL-15. MDMA also suppresses innate IFN-γ production, and considering the role of IFN-γ in priming antigen-presenting cells, it is not surprising that MDMA reduces MHC class II expression on dendritic cells and macrophages, and inhibits co-stimulatory molecule expression. Paradoxically, studies demonstrate that MDMA elicits pro-inflammatory actions in the CNS by activating microglia, the resident innate immune cells in the brain. In terms of adaptive immunity, MDMA reduces circulating lymphocyte numbers, particularly CD4+ T-cells; suppresses T-cell proliferation; and skews cytokine production in a Th2 direction. For the most part, the immunosuppressive effects of MDMA cannot be attributed to a direct action of the drug on immune cells, but rather due to the release of endogenous immunomodulatory substances. In this regard, peripheral β-adrenoceptors and cholinergic receptors have been shown to mediate some immunosuppressive effects of MDMA. Finally, we discuss emerging evidence indicating that MDMA-induced immunosuppression can translate into significant health risks for abusers.

Sanitizing the Psychedelic Revolution
Big Pharma is rushing to monetize ancient healing practices, but what’s left might not be the same medicine

What Are Psychedelic Entities?
The beings people often meet while using psychedelics resist tidy explanations.

Psilocybin Treatment for Major Depression Effective for Up to a Year for Most Patients, Study Shows
Previous studies by Johns Hopkins Medicine researchers showed that psychedelic treatment with psilocybin relieved major depressive disorder symptoms in adults for up to a month. Now, in a follow-up study of those participants, the researchers report that the substantial antidepressant effects of psilocybin-assisted therapy, given with supportive psychotherapy, may last at least a year for some patients.

Can Psychedelics Make Us More Moral?
With a renaissance going on in psychedelic research, is making us better people included?

Let’s Talk About Bad Trips: Separating Difficult from Traumatic Psychedelic Support
Bad trips are a polarizing concept in psychedelics. Acknowledging that they exist - and knowing how to work with them - can be healing.

Jonathan Pageau's Psychedelic Warning
Mushrooms evolved psychedelics twice, baffling scientists
Researchers found that magic mushrooms and fiber caps independently evolved different biochemical pathways to create psilocybin. This convergence shows nature’s ingenuity, but the reason why remains unknown—possibly predator deterrence. Beyond evolutionary mystery, the discovery provides new enzyme tools for biotech, with promising applications for producing psilocybin-based medicines.

Psilocybin induces rapid and persistent growth of neural connections in the brain's frontal cortex, study finds
Yale scientists have found that a single dose of psilocybin given to mice induces a rapid and long-lasting increase in connections between pyramidal
